Drug General Information
Drug ID	D0D8VU
Former ID	DIB006225
Drug Name	LGD-6972
Indication	Type 2 diabetes [ICD9: 250; ICD10:E11]		Phase 1	[524930]
Company	Ligand pharmaceuticals
Structure		Download 2D MOL
Target and Pathway
Target(s)	Glucagon receptor	Target Info	Antagonist	[544477]
KEGG Pathway	Neuroactive ligand-receptor interaction
	Glucagon signaling pathway
Reactome	Glucagon signaling in metabolic regulation
	G alpha (q) signalling events
	G alpha (s) signalling events
	Glucagon-type ligand receptors
WikiPathways	GPCRs, Class B Secretin-like
	Gastrin-CREB signalling pathway via PKC and MAPK
	Integration of energy metabolism
	GPCR ligand binding
	GPCR downstream signaling
References
Ref 524930	ClinicalTrials.gov (NCT02250222) Safety and Tolerability Study of Oral LGD-6972 for Type 2 Diabetes Mellitus. U.S. National Institutes of Health.
Ref 544477	Addressing Unmet Medical Needs in Type 2 Diabetes: A Narrative Review of Drugs under Development. Curr Diabetes Rev. 2015 March; 11(1): 17-31.

If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.